ALPHARETTA, Ga., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to ...

Using a new and dramatically effective treatment approach, scientists at the Scripps Research Institute have for the first time achieved complete inhibition of new blood vessel growth in animal models ...

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...

Phase 2 study of atezolizumab with carboplatin plus pemetrexed followed by maintenance atezolizumab with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: ...

Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment The following represents disclosure information provided by authors of this manuscript. All relationships are ...

Tuberculosis bacteria escape the little pellets of immune system containment called granulomas with the help of new blood vessels that tunnel into the clusters to provide fresh oxygen and an escape ...

Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in patients with neurofibromatosis type 2 (NF2). In a paper to appear in the July 23 New England ...

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...